Mental and behavioural disorders due to cocaine

F5_COCAINE

cocaine dependence: A psychologically and socially impaired state, with or without physiological changes, that develops as a result of using cocaine and which leads to compulsive behaviors to acquire the substance.

Suggest a new description

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — F14 Hospital discharge: ICD-9 — 3042\|3056 Hospital discharge: ICD-8 — 3044 Cause of death: ICD-10 — F14 Cause of death: ICD-9 — 3042\|3056 Cause of death: ICD-8 — 3044 2 out of 7 registries used, show all original rules.	59
4. Check minimum number of events None	59
5. Include endpoints None	59
6. Filter based on genotype QC (FinnGen only)	59

Control definitions (FinnGen only)

Control exclude: F5_SUBSNOALCO

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: F10-F19
Name in latin: Perturbationes mentis et modi se gerendi ex usu cocaini

NAME	F5_COCAINE
CONTROL_EXCLUDE	F5_SUBSNOALCO
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	F14
HD_ICD_9	3042\|3056
HD_ICD_8	3044
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	F14
COD_ICD_9	3042\|3056
COD_ICD_8	3044
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Mental and behavioural disorders due to cocaine based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	540	155	381
Only index persons	457	137	320
Unadjusted period prevalence (%)
Whole population	0.01	0.00	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	30.18	29.30	30.44
Only index persons	29.08	27.60	29.71

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	59	19	40
Unadjusted period prevalence (%)	0.01	0.01	0.02
Median age at first event (years)	31.79	27.05	34.03

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
50: Matched controls
497

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

B18.2

ICD-10 Finland

Chronic viral hepatitis C

+∞

16.6

F19.29

ICD-10 Finland

Addiction caused by several drugs in combination and by other psychoactive substances UNS

+∞

13.1

F15.2

ICD-10 Finland

Mental and behavioural disorders due to use of other stimulants, including caffeine, dependence syndrome

+∞

11.9

F29

ICD-10 Finland

Unspecified nonorganic psychosis

22.7

11.3

P19

ICPC

Drug abuse

137.7

10.9

N03AG01

ATC

valproic acid; systemic, rectal

18.9

10.6

N05AH03

ATC

olanzapine; systemic

18.9

10.6

N05BA01

ATC

diazepam; systemic, rectal

11.2

10.5

X69

ICD-10 Finland

Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances

20.7

10.3

T36

ICD-10 Finland

Poisoning by systemic antibiotics

17.4

10.3

N05AA02

ATC

levomepromazine; systemic

28.5

10.0

N05BA04

ATC

oxazepam; oral

7.8

9.9

F39

ICD-10 Finland

Unspecified mood [affective] disorder

122.2

9.8

N05AH04

ATC

quetiapine; oral

7.7

9.6

F60.9

ICD-10 Finland

Personality disorder, unspecified

45.9

9.5

N05CF01

ATC

zopiclone; oral

7.2

9.3

112

Kela drug reimbursment

Severe psychotic and other severe mental disorders

11.1

9.2

ICZ03

NOMESCO Finland

Participation in compiling a psychiatric treatment plan

61.1

9.0

IEY05

NOMESCO Finland

Dedicated profession-specific psychiatric intervention, individual

34.4

8.9

F14.1

ICD-10 Finland

Mental and behavioural disorders due to use of cocaine, harmful use

+∞

8.6

ZY010

NOMESCO Finland

Hospital outpatient

17.0

8.4

F10.1

ICD-10 Finland

Mental and behavioural disorders due to use of alcohol, Harmful use

14.4

8.4

N07BB01

ATC

disulfiram; oral

27.5

8.4

F10.29

ICD-10 Finland

Addiction caused by alcohol UNS

40.7

8.4

R56.8

ICD-10 Finland

Other and unspecified convulsions

19.2

8.2

Z2446

NOMESCO Finland

Social worker

13.4

8.2

N03AE01

ATC

clonazepam; systemic

15.4

8.1

N05CD07

ATC

temazepam; oral

10.8

7.8

N06AB06

ATC

sertraline; oral

8.3

7.5

F19.20

ICD-10 Finland

Addiction relationship caused by several drugs in combination and by other psychoactive substances currently independent

+∞

7.5

3042A

ICD-9 Finland

Drug dependence, Cocaine dependence

+∞

7.5

F13.25

ICD-10 Finland

Addiction caused by sedative and hypnotic continuous use

+∞

7.5

F15.1

ICD-10 Finland

Mental and behavioural disorders due to use of other stimulants, including caffeine, harmful use

+∞

7.5

F19.1

ICD-10 Finland

Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances, harmful use

+∞

7.5

F19.21

ICD-10 Finland

Addiction caused by several drugs in combination and by other psychoactive substances currently independent but staying in a controlling environment

+∞

7.5

F13.20

ICD-10 Finland

Addiction relationship caused by sedatives and hypnotics currently independent

+∞

7.5

F60.30

ICD-10 Finland

Emotionally unstable personality disorder, impulsive

20.3

7.1

Z3231

NOMESCO Finland

Registered nurse

5.8

7.1

ICB01

NOMESCO Finland

Psychiatric treatment plan, standard

46.5

7.0

F60.31

ICD-10 Finland

Emotionally unstable personality disorder, borderline condition

46.5

7.0

N05AA01

ATC

chlorpromazine; systemic, rectal

46.5

7.0

Z2221

NOMESCO Finland

Medical doctor

5.7

6.9

F20.9

ICD-10 Finland

Schizophrenia, unspecified

26.8

6.9

F10.20

ICD-10 Finland

Alcohol dependence currently independent

26.8

6.9

Z00.4

ICD-10 Finland

General psychiatric examination, not elsewhere classified

7.6

6.7

ICB02

NOMESCO Finland

Psychiatric treatment plan, extended/prolonged

79.6

6.6

F32.3

ICD-10 Finland

Severe depressive episode with psychotic symptoms

31.0

6.4

WYA30

NOMESCO Finland

Preparations for expected poor cooperation

9.3

6.4

X57

ICD-10 Finland

Unspecified privation

+∞

6.4

F11.22

ICD-10 Finland

Addiction-induced dependence is currently independent but uses substitute intermittent medication

+∞

6.4

F11.21

ICD-10 Finland

Addiction-indiced dependence caused by opiates currently independent but staying in controlling environment

+∞

6.4

F13.29

ICD-10 Finland

Addiction caused by sedative and hypnotic UNS

+∞

6.4

F11.25

ICD-10 Finland

Relationship caused by opiates continuously used

+∞

6.4

N06AX16

ATC

venlafaxine; oral

6.1

6.3

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(3028707) Methadone [Presence] in Urine by Screen method

19.49

20.26

19.5

1.5

—

(3011288) Drugs identified in Urine by Screen method

13.62

18.50

26.5

1.5

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

10.73

14.47

18.5

1.4

—

(3016879) Cocaine [Presence] in Urine

9.04

13.53

17.3

1.4

—

(3027944) Amphetamines [Presence] in Urine

8.50

12.83

7.9

1.4

—

(3027008) Opiates [Presence] in Urine

8.50

12.83

17.4

1.4

—

(3000764) Benzodiazepines [Presence] in Urine

8.50

12.83

17.4

1.4

—

(3028300) Cannabinoids [Presence] in Urine

8.50

12.83

17.5

1.4

—

(3021125) Hepatitis C virus RNA [Presence] in Serum or Plasma by NAA with probe detection

26.46

8.36

2.1

1.2

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

6.49

7.38

1.6

1.3

—

(42870588) Differential panel, method unspecified - Blood

134

4.32

7.20

6.2

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

4.89

7.05

1.9

1.4

—

(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method

19.64

7.02

3.3

1.2

—

(40758558) Short blood count panel - Blood

103

4.27

6.95

8.2

6.9

—

(3007628) Bicarbonate [Moles/volume] standard in Venous blood

8.40

6.92

3.4

3.8

mmol/l

23.6

24.4

—

(3021589) Normoblasts [#/volume] in Blood

199

4.48

6.90

10.4

8.0

e9/l

0.0

0.50

162

(3024354) Oxygen [Partial pressure] in Venous blood

6.92

6.90

2.1

2.6

kpa

5.8

4.5

0.65

(3017143) Hepatitis C virus Ab [Presence] in Serum

4.37

6.88

2.1

1.6

—

(3021447) Carbon dioxide [Partial pressure] in Venous blood

6.02

6.04

3.0

4.9

kpa

5.8

6.0

0.48

(3012544) pH of Venous blood

6.02

6.04

3.0

5.8

—

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

165

3.76

5.86

5.3

10.3

mmol/l

1.2

0.48

145

(3008832) Norclozapine [Moles/volume] in Serum or Plasma

18.16

5.58

15.7

12.4

nmol/l

861.5

601.0

—

(3000081) cloZAPine [Moles/volume] in Serum or Plasma

18.16

5.58

19.0

18.2

nmol/l

1308.7

938.8

—

(3015736) pH of Urine

164

3.53

5.37

3.4

2.7

—

(3009466) Valproate [Moles/volume] in Serum or Plasma

15.12

5.24

4.5

4.2

umol/l

416.3

277.2

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

272

4.14

5.23

14.7

8.5

e9/l

4.1

3.9

0.16

236

(46235355) HIV 1 and 2 tests - Meaningful Use set

145

3.40

5.07

3.2

2.0

—

(3033658) Prothrombin time (PT) actual/Normal

112

3.36

4.81

6.1

3.8

89.7

94.9

0.50

112

(3021960) Folate [Moles/volume] in Serum or Plasma

3.63

4.78

1.3

1.4

nmol/l

20.4

20.6

0.03

(3023368) Bacteria identified in Blood by Culture

3.37

4.60

7.3

4.8

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

123

3.20

4.51

2.0

1.5

pmol/l

96.3

100.9

0.22

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

313

3.86

4.26

3.8

pmol/l

14.2

14.8

1.00

298

(3001604) Monocytes [#/volume] in Blood

225

3.16

4.25

9.3

5.5

e9/l

0.7

0.6

1.20

201

(3006315) Basophils [#/volume] in Blood

226

3.14

4.20

9.3

5.5

e9/l

0.0

0.15

204

(3019198) Lymphocytes [#/volume] in Blood

230

3.05

4.00

9.3

5.6

e9/l

2.2

1.8

1.63

211

(3013115) Eosinophils [#/volume] in Blood

231

3.03

3.96

9.4

6.0

e9/l

0.2

0.06

210

(3018095) Leukocytes [#/volume] in Urine

132

2.93

3.88

3.8

3.4

e6/l

182.0

138.9

0.09

(3000991) Gas panel - Venous blood

4.28

3.84

6.7

8.1

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

3.02

3.79

2.8

2.3

—

(1761868) Lipid panel - Serum or Plasma

205

0.25

3.67

2.3

2.1

—

(3052851) Hemolysis interference index of Serum or Plasma

8.18

3.13

2.0

4.2

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

2.78

3.05

2.5

2.1

—

(3012516) Albumin [Mass/volume] in Urine

2.80

2.98

3.4

3.3

mg/l

3762.7

925.2

0.33

(44816559) Phosphatidylethanol [Mass/volume] in Blood

4.69

2.79

1.6

1.2

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

113

2.51

2.72

2.5

1.7

—

(3019150) Specific gravity of Urine by Refractometry

106

2.52

2.69

3.6

3.0

—

1.0

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

4.45

2.67

2.9

4.7

mmol/l

25.3

25.1

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

4.23

2.57

1.8

1.2

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

4.23

2.57

1.3

1.2

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

5.43

2.46

3.5

2.7

ug/l

203.0

192.4

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

2.44

2.40

2.2

2.7

—

(3007853) Bacteria identified in Skin by Aerobe culture

2.81

2.40

1.5

1.6

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

2.56

2.35

1.8

3.6

ng/l

156.8

46.4

—

(3020630) Protein [Mass/volume] in Serum or Plasma

4.26

2.33

1.3

4.8

g/l

66.9

66.7

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

3.05

2.23

3.9

2.3

—

(3023103) Potassium [Moles/volume] in Serum or Plasma

453

3.26

2.12

19.1

12.2

mmol/l

3.9

4.0

0.91

438

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

5.34

2.11

1.0

1.1

—

(3000924) Streptococcus pyogenes [Presence] in Throat by Organism specific culture

5.34

2.11

1.4

1.1

—

(3030467) Casts [#/volume] in Urine by Automated count

109

2.26

2.11

3.6

2.7

e6/l

0.0

0.3

1.41

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

4.32

2.09

1.7

—

(3042936) Bacteria identified in Isolate by Culture

2.53

1.89

3.3

2.7

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

3.03

1.87

1.6

1.3

—

(3002582) Erythrocytes [#/volume] in Urine

118

2.05

1.69

3.6

2.7

e6/l

18.4

19.2

0.04

(3004588) Protein electrophoresis panel - Serum or Plasma

3.80

1.65

1.4

3.4

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

3.80

1.65

1.2

1.1

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

1.58

0.0

1.2

—

(36304419) Bacteria [Presence] in Urine

113

2.01

1.56

3.7

2.6

—

(3044889) 12 lead EKG panel

309

1.91

1.48

3.2

3.0

—

(3004119) Hemoglobin [Mass/volume] in Venous blood

3.31

1.47

2.8

6.0

g/l

109.8

124.6

—

(3019832) Treponema pallidum Ab [Presence] in Serum

2.05

1.43

2.9

1.7

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

437

2.23

1.41

18.0

8.7

ml/min/173m2

101.0

93.8

1.33

351

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

2.29

1.37

3.7

2.0

—

(3007164) IgA [Mass/volume] in Serum or Plasma

102

1.94

1.35

1.2

1.5

g/l

3.4

2.3

0.90

(3002385) Erythrocyte distribution width [Ratio]

414

2.08

1.28

30.3

13.8

13.6

13.3

0.86

407

(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood

2.63

1.17

8.4

11.7

0.8

1.9

—

(3006217) Methemoglobin/Hemoglobin.total in Arterial blood

2.63

1.17

8.4

11.7

0.4

0.7

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

134

1.75

1.11

3.7

2.6

—

(3014007) Fractional oxyhemoglobin in Arterial blood

2.50

1.11

8.4

11.4

96.0

94.8

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

2.27

1.10

4.1

2.0

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.08

1.08

1.7

1.5

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.03

1.06

1.8

1.5

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

110

1.77

1.05

1.0

1.3

u/ml

0.7

1.2

—

(3019060) Gas panel - Arterial blood

0.00

1.01

0.0

21.2

—

(3025941) Bacteria identified in Stool by Culture

0.00

0.99

0.0

1.1

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

1.92

0.98

2.5

1.7

—

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

370

1.60

0.80

4.8

2.9

u/l

49.6

39.8

0.53

358

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

2.28

0.78

7.2

31.4

—

(3037467) Urinalysis macro (dipstick) panel - Urine

289

1.52

0.77

4.2

3.5

—

(3044640) Blood type and Crossmatch panel - Blood

120

1.59

0.75

3.0

2.3

—

(3018677) aPTT in Platelet poor plasma by Coagulation assay

1.77

0.74

2.2

31.5

30.6

—

(3031040) Bacteria [#/volume] in Urine by Automated count

255

1.45

0.67

5.0

3.7

—

22.6

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.61

0.0

1.2

—

(3003740) Influenza virus B Ag [Presence] in Specimen

0.00

0.60

0.0

1.2

—

(3002523) Influenza virus A Ag [Presence] in Specimen

0.00

0.60

0.0

1.2

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

133

1.39

0.45

4.4

2.8

ng/l

11.6

25.1

—

(40768804) Tissue Pathology biopsy report

152

1.37

0.44

2.7

1.8

—

(36660697) Celiac disease serology panel - Serum

1.61

0.43

1.0

1.3

—

(3026008) Bacteria identified in Urine by Culture

1.46

0.42

3.0

2.4

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

1.44

0.42

3.3

2.4

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

0.00

0.42

0.0

2.5

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

0.00

0.42

0.0

2.9

—

24.7

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

0.00

0.42

0.0

1.0

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.42

0.0

1.5

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.42

0.0

1.2

—

(3003694) ABO and Rh group [Type] in Blood

156

0.71

0.41

2.4

1.5

—

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

0.00

0.40

0.0

1.1

—

(42529406) Shigella sp [Presence] in Stool by Culture

0.00

0.40

0.0

1.1

—

(3014765) Yersinia sp identified in Stool by Organism specific culture

0.00

0.40

0.0

1.1

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.40

0.0

1.3

—

(3041096) Erythrocytes [Presence] in Urine by Automated

123

0.68

0.40

6.1

2.6

—

(3013512) EKG study

1.40

0.37

6.3

2.4

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

111

1.34

0.34

1.7

—

(3000492) Spirometry study

1.36

0.30

1.1

1.5

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

453

1.32

0.28

3.7

3.2

mmol/l

1.7

1.3

1.40

429

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.66

0.28

1.2

1.5

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

168

0.78

0.27

4.9

2.7

—

(3003396) Base excess in Arterial blood by calculation

1.31

0.23

9.6

22.4

mmol/l

-1.0

1.7

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.21

0.0

1.4

—

(3043409) Potassium [Moles/volume] in Arterial blood

0.00

0.21

0.0

6.3

—

3.9

—

(4094501)

0.00

0.21

0.0

1.0

—

(3037551) Cancer Ag 125 [Units/volume] in Serum or Plasma

0.00

0.21

0.0

1.4

—

15.8

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.1

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.8

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

0.21

0.0

2.0

—

(3022313) Gas panel - Capillary blood

0.00

0.21

0.0

3.2

—

(3018405) Lactate [Moles/volume] in Arterial blood

0.00

0.21

0.0

10.8

—

1.4

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.20

0.0

2.6

—

(3009542) Hematocrit [Volume Fraction] of Blood

470

1.25

0.19

29.7

12.0

39.6

42.0

1.13

407

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

191

1.15

0.14

4.8

4.6

—

(3022145) Colonoscopy Study observation

1.15

0.10

1.2

1.4

—

(3000494) Fungus identified in Specimen by Culture

1.08

0.09

1.7

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

0.79

0.08

2.2

1.5

—

(40761511) CBC panel - Blood by Automated count

496

0.93

0.01

17.7

10.0

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

395

0.96

0.00

4.1

3.7

—

(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay

0.00

0.0

2.8

—

106.3

—

(40760892) CBC W Ordered Manual Differential panel - Blood

110

1.00

0.00

10.5

3.8

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

0.00

0.0

2.0

—

(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

0.0

1.0

—

121.3

—

(3033306) Mononuclear cells/100 leukocytes in Cerebral spinal fluid

0.00

0.0

1.2

—

(3005082) Progesterone [Moles/volume] in Serum or Plasma

0.00

0.0

1.3

—

25.3

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

0.0

1.0

—

(3018658) Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(3000093) Morphology [Interpretation] in Blood Narrative

0.00

0.0

1.6

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.2

—

(40768441) Liver Pathology biopsy report

0.00

0.0

1.0

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

6.6

—

13.1

—

(3053028) Streptococcus sp identified in Specimen by Organism specific culture

0.00

0.0

1.0

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

0.00

0.0

1.1

—

(3026389) Candida sp identified in Specimen by Organism specific culture

0.00

0.0

1.2

—

(3007847) Interleukin 2 Receptor Soluble [Units/volume] in Serum or Plasma

0.00

0.0

2.4

—

851.0

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.3

—

(3021236) Streptolysin O Ab [Units/volume] in Serum or Plasma

0.00

0.0

1.0

—

300.6

—

(3018387) Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum

0.00

0.0

1.3

—

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.6

—

(3023420) DNA double strand Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(21492711) Cytomegalovirus IgG Ab avidity [Presence] in Serum or Plasma by Immunoassay

0.00

0.0

1.1

—

(3015183) Erythrocyte sedimentation rate

0.00

0.0

1.0

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

0.0

1.4

—

(40768806) Pleura Pathology biopsy report

0.00

0.0

2.3

—

(3021788) Differential panel - Synovial fluid

0.00

0.0

1.4

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

0.0

1.7

—

(4268621)

0.00

0.0

2.6

—

(40764126) Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.2

—

(3032773) Endomysium IgG Ab [Titer] in Serum

0.00

0.0

1.0

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

0.0

5.8

—

1.6

—

(3016244) Insulin [Units/volume] in Serum or Plasma

0.00

0.0

1.8

—

23.3

—

(3019897) Erythrocyte distribution width [Ratio] by Automated count

0.00

0.0

1.2

—

12.6

—

(3025149) Bordetella pertussis IgA Ab [Units/volume] in Serum

0.00

0.0

1.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint F5_COCAINE and mortality.

Females

No data

Males

Parameter	HR [95% CI]	p-value
F5_COCAINE	5.817 [3.31, 10.22]	< 0.001
Birth year	0.985 [0.98, 0.99]	0.002

During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 271 males with F5_COCAINE died.

Mortality risk

Mortality risk for people of age

years, who have F5_COCAINE.

N-year risk	Females	Males
1	No data	0.888%
5	No data	6.195%
10	No data	14.98%
15	No data	26.713%
20	No data	42.334%

Relationships between endpoints

↥

Index endpoint: F5_COCAINE – Mental and behavioural disorders due to cocaine

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

Extremity

rg [CI]

Extremity

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Mental and behavioural disorders due to cocaine

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints